Daptacel dtap vaccine 0.5ML
Ended Awarded
- Contract number
- SPE2DB26FKXVP
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,024
Award facts
- Contract value 100% obligated
- $1,023.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $1,023.60 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Daptacel DTAP vaccine in 0.5mL dosages. The delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order represents one of numerous recent awards issued to DMS Pharmaceutical Group by the Defense Logistics Agency's Medical Supply Chain division, reflecting the company's established role as a critical pharmaceutical supplier to Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. The parent IDC, awarded on November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, positioning the company as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy. The IDC authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products and medical consumables to support recurring medical supply needs of military healthcare facilities worldwide, with DMS Pharmaceutical Group's consistent contract performance across multiple therapeutic categories demonstrating its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DB26FKXVP?
SPE2DB26FKXVP was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FKXVP worth?
The government has obligated $1,024 on SPE2DB26FKXVP.
Is contract SPE2DB26FKXVP an order under another contract?
Yes. SPE2DB26FKXVP is a delivery order under SPE2DB24D9801, an indefinite delivery contract.
Was contract SPE2DB26FKXVP competed?
The extent of competition for SPE2DB26FKXVP was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award